ERBB2 and gastric adenocarcinoma: Up to 30% of esophago-gastric adenocarcinomas have ERBB-2 (or HER2) oncogenic amplifications, which have been successfully clinically targeted with a combination of systemic chemotherapy and anti-HER2 therapy in the form of trastuzumab for almost a decade, as demonstrated by the ToGA trial.